Primary effusion lymphoma (PEL) selectively involves the serous body cavities, occurs predominantly in immunodeficient patients and is infected consistently by human herpesvirus type-8. PEL is also frequently infected by EpsteinBarr virus (EBV). The precise pathogenetic role of EBV coinfection in PEL is not fully understood. The lymphoma fails to express the EBV transforming proteins EBNA-2 and LMP-1, whereas it expresses EBNA-1 (latency I phenotype). Some studies have hypothesized that other EBV-positive lymphomas expressing the latency I phenotype may associate with specific molecular variants of EBNA-1, although this issue has not been addressed in PEL. On this basis, this study is aimed at a detailed molecular characterization of EBV in PEL. Leukemia (2000) 14, 271-277.
Introduction
Primary effusion lymphoma (PEL) is a peculiar type of B cell non-Hodgkin's lymphoma (NHL) occurring predominantly, though not exclusively, in human immunodeficiency virus (HIV) positive patients. [1] [2] [3] [4] Other immunodeficiency conditions, namely post-transplant immunodeficiency, have also been associated with PEL. 5, 6 Recently, PEL has been recognized as a unique lymphoma entity based on its distinctive features which include presentation as lymphomatous effusion in the serous body cavities and consistent infection of the tumor clone by human herpesvirus type 8 (HHV-8). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In
Correspondence: G Gaidano, Division of Internal Medicine, Department of Medical Sciences, Amedeo Avogadro University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; Fax 39 0321 620-421 Received 6 July 1999; accepted 14 October 1999 addition to HHV-8, PEL cells are also frequently co-infected by Epstein-Barr virus (EBV). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 12 The role of viral infection in PEL pathogenesis is not fully understood. On the one hand, the pathogenetic role of HHV-8 is suggested by the consistency of infection and by the expression of a subset of HHV-8 genes in PEL cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 13, 14 On the other hand, the pathogenetic contribution of EBV is unclear. In fact, EBV infection occurs in 70% of PEL, is typically latent, and is generally monoclonal, suggesting that the virus infects the tumor cells since the early phases of clonal expansion. [1] [2] [3] [4] [5] [6] [7] [8] [9] 12 However, EBV-positive PEL fail to express the viral transforming antigens EBNA-2 and LMP-1, which are key inducers of the transformed phenotype in B cells. 12 Rather, the expression of EBV latent genes in PEL is restricted to EBNA-1, a gene required for replication and maintenance of viral episomes and displaying some oncogenic potential, though probably not sufficient for tumorigenicity. 12, [15] [16] [17] [18] In this respect, the profile of EBV antigen expression in PEL may be classified as latency I, ie positive EBNA-1 expression in the absence of EBNA-2 and LMP-1, and thus closely reflects the phenotypic profile of EBV-positive Burkitt lymphoma. 12, [19] [20] [21] Some studies have hypothesized that, in EBV-positive lymphomas displaying the latency I phenotype, viral tumorigenicity may be ascribed to specific mutations in the DNA binding/dimerization domain of the EBNA-1 gene. [22] [23] [24] Such mutations identify two major EBV strains, termed as strain P (prototype) and V (variant). Each strain can be further subdivided according to signature changes at position 487, leading to the recognition of several major EBV subtypes. The EBNA-1 variants originally described were P-ala, which is identical to the prototype virus B95.8; P-thr, representing a subtype closely related to P-ala; and three more distant variants termed V-leu, V-pro and V-val. [22] [23] [24] Subsequently, several other EBNA-1 variants have also been reported. [25] [26] [27] [28] This study aimed at defining the distribution of EBNA-1 variants in PEL and at comparing it with the representation of EBNA-1 in non-neoplastic B cells from HIV-infected individuals. In order to further characterize the EBV genotype of PEL, several other molecular features of the virus were also investigated.
Materials and methods

Tumor panel, normal controls and DNA extraction
The present study is based on a panel of 15 samples of PEL (13 primary cases and two cell lines) associated with EBV infection of the tumor clone. The panel includes AIDS-related
Leukemia PEL (n = 12), post-transplant PEL (n = 1), as well as PEL arising in immunocompetent hosts (n = 2). Diagnosis of PEL was established based on previously reported criteria. 1, 7, 11 The two PEL cell lines included in this study (BC-1 and BC-2) have been characterized in detail previously. [29] [30] [31] Normal, ie nonneoplastic, controls were represented by peripheral blood mononuclear cells (PBMNC) obtained from HIV-positive individuals (n = 12) with no evidence of lymphoma. DNA was prepared as previously reported. 2 
Determination of EBNA-1 variants in PEL
The distribution of EBNA-1 variants in PEL was determined by DNA direct sequencing of polymerase chain reaction (PCR) amplified products. DNA samples of PEL were amplified by a single-step PCR protocol using primers EBNA-1/5Ј and EBNA-1/3Ј that amplify a 330 bp fragment (Table 1) , containing most substitutions observed in variant subtypes. 22 DNA samples from PBMNC were analyzed by seminested PCR using primers EBNA-1/5Ј and EBNA-1/3Ј followed by EBNA-1/5Ј and EBNA-1/3Јb that amplify a 324 bp amplimer (Table 1) . 22 PCR was performed in a final volume of 50 l containing 500 ng DNA, 50 pmol of each primer, 100 M dNTPs, 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin and 2.5 U AmpliTaq polymerase (Perkin-Elmer, Norwalk, CT, USA) and by using an Omn-E thermocycler (Hybaid, Teddington, UK). Sequence of primers and annealing temperatures are shown in Table 1 . After PCR, the DNA amplimers were purified (QIAquick gel extraction kit, Qiagen, CA, USA) and subjected to DNA direct sequencing using a commercially available kit (Thermosequenase, Amersham Life Science, Amersham, UK).
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P-labeled terminator dideoxynucleotides were included in the sequencing mixture. All sequences obtained were compared to the DNA sequence of B95.8, which represents the EBV prototype. 32 In selected cases (n = 5), mutation analysis of EBNA-1 was also performed after subcloning of the PCR amplimer into the pCRII vector.
Analysis of LMP-1 gene in PEL
Heterogeneity of the LMP-1 gene was investigated by PCR analysis using primers LMP-1/5Ј and LMP-1/3Ј which explore the carboxyterminus of LMP-1 ( bp), ⌬30LMP-1 (amplimer size = 131 bp) and ⌬69LMP-1 (amplimer size = 92 bp). 33, 34 The PCR reaction was performed as described above. The EBV positive cell lines B95.8 and AG876 were used as control for wild-type LMP-1 and ⌬30LMP-1, respectively. PCR products were analyzed on a 3% agarose gel and the size of PEL-derived amplimers was compared to that obtained from controls. Cases exhibiting an amplimer size equivalent to that obtained with B95.8 were interpreted as containing a wild-type LMP-1 gene. Cases exhibiting an amplimer size equivalent to that obtained with AG876 were interpreted as containing a ⌬30LMP-1 gene and were further subjected to DNA sequence analysis for confirmation.
Definition of EBV type-1/type-2 in PEL
Definition of EBV type-1/type-2 was performed by PCR using primers specific for the EBNA-2 and EBNA-3C genes, as previously reported. 33, 35 The sequence of primers EBNA-2/5Ј and EBNA-2/3Ј (for EBNA-2) and EBNA-3C/5Ј and EBNA-3C/3Ј (for EBNA-3C) are reported in Table 1 . PCR reactions were performed as described above; annealing temperatures are specified in Table 1 . The EBV positive cell lines B95.8 and AG876 were used as controls for EBV type-1 and EBV type-2, respectively. PCR products from PEL samples and from controls were analyzed on a 2% agarose gel. Cases exhibiting a size of the amplimer equivalent to that obtained with B95.8 were interpreted as containing EBV type-1. Cases exhibiting a size of the amplimer equivalent to that obtained with AG876 were interpreted as containing EBV type-2.
Results
Characteristics of the tumor panel and of controls
The characteristics of the PEL samples included in this study are summarized in Table 2 . Twelve PEL were AIDS-related, one case developed post-transplant and two cases developed in individuals with no apparent immunodeficiency. The ethnic background of PEL patients was Western Europe (Caucasian patients), including Italy (n = 12) and France (n = 1). The two PEL cell lines investigated were derived from patients of North American origin. Cases used as controls were representative of HIV-positive individuals of Caucasian background from Western Europe.
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Analysis of EBNA-1 variation in PEL
The carboxyterminus of the EBNA-1 gene, which displays a high degree of variation in EBV infected cells, was sequenced in 11 PEL samples for which sufficient DNA was available. In each PEL investigated, a single EBNA-1 variant was detected, consistent with infection by a single EBV strain. When compared to the sequence of the B95.8 EBV prototype, the EBNA-1 gene harbored by PEL displayed a variable number of mutations. Representative examples of EBNA-1 mutations in PEL are shown in Figure 1 , whereas the partial sequences of the EBNA-1 gene harbored by each PEL analyzed are reported in Figure 2 . The EBNA-1 variants displayed by individual PEL cases are listed in Table 2, whereas Table 3 summarizes the type and frequency of EBNA-1 mutations detected in these lymphomas. The mutated EBNA-1 genes harbored by PEL were classified according to the nomenclature system proposed by Bhatia et al. [22] [23] [24] EBNA-1 sequences have been submitted to Genbank (accession numbers AF192740-AF192745). On this basis, the EBNA-1 gene of one PEL (BC-1) was assigned to the P-ala subtype, since it was identical to the B95.8 EBV prototype (Table 2 and Figure 2 ). In two PEL (cases 2237 and 2096), EBNA-1 was classified as subvariants of P-ala, because of the presence of aminoacid substitutions not present in the original P-ala (Table 2 and Figure 2 ). In seven PEL (cases 1910, 2301, 2265, 2258, 1650, 2243, BC-2), the EBNA-1 gene was classified as subvariants of P-thr because of the presence of threonine at position 487 and a number of additional mutations not present in the original P-thr sequence (Table 2 and Figure  2 ). The occurrence of P-thr subvariants in PEL is consistent with previous observations obtained from other human malignancies. [25] [26] [27] [28] Finally, the EBNA-1 variant V-leu, was restricted to one single case of PEL (case 1911; Table 2 and Figure 2) . In selected cases (n = 5), analysis of multiple subclones (n = 5) showed absence of intratumor heterogeneity of the EBNA-1 mutations. Overall, the distribution of EBNA-1 mutations in PEL did not significantly differ from that detected in HIVLeukemia related lymphomas other than PEL (n = 10; Fassone et al., submitted).
EBNA-1 subtype in PBMNC from HIV-infected individuals without lymphoma
All 12 samples of PBMNC obtained from HIV-infected individuals without lymphoma had EBNA-1 gene sequences that differed from the prototype EBNA-1 P-ala. The mutation pattern of EBNA-1 detected in PBMNC from HIV-infected individuals is described in Table 3 and was overall similar to that found in PEL samples. Nine cases of PBMNC from HIVinfected individuals carried multiple EBNA-1 subtypes, consistent with the occurrence of multiple EBV infections in these patients.
36,37
Analysis of LMP-1 in PEL
The prevalence of deletions in the carboxyterminal portion of the LMP-1 gene was investigated in 15 cases of EBV-associated PEL. A full length LMP-1 fragment was detectable in 10/15 cases (67%; Table 2 ). Five of 15 (33%) PEL samples harbored a LMP-1 variant harboring a 30 bp deletion (⌬30LMP-1) which was similar to that of the AG876 cell line, known to harbor ⌬30LMP-1 ( Table 2) . 38 The ⌬30LMP-1 variants detected in PEL were further characterized by DNA sequencing analysis which, in all cases, confirmed the location of a deletion spanning from codon 346 (nucleotide 168285) to codon 355 (nucleotide 168256), identical to that of the ⌬30LMP-1 variant associated with AG876 ( Figure 3) . Similar to AG876, 39 all the ⌬30LMP-1 variants detected in PEL displayed point mutations at nucleotides 168320 (A→G), 168308 (T→C) and 168225 (T→A), leading to aminoacid substitutions in codons 334 (Gln→Arg), 338 (Leu→Ser) and 366 (Ser→Thr) (Figure 3) . In the PEL cell line BC-1, an additional point mutation was detected at nucleotide 168318 (G→A) 22 On this basis, B95.8 harbored the P-ala variant of EBNA-1, whereas cases 2301 and 1911 harbored the P-thrЈ and V-leu EBNA-1 variants, respectively.
Figure 2
Alignments of EBNA-1 sequences in samples of EBV positive primary effusion lymphoma (PEL). The Figure shows the partial sequence of the carboxyterminal region of EBNA-1 amplified from EBV associated PEL. Primary samples of PEL are indicated by a numbered code, whereas PEL cell lines are indicated by their conventional denomination. For comparison, the EBNA-1 sequence of the EBV prototype B95.8 is also shown. The EBNA-1 variant harbored by individual PEL samples is defined based on the nomenclature proposed by Bhatia et al. leading to aminoacid substitution in codon 335 (Gly→Ser) (Figure 3) .
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Definition of type-1/type-2 EBV infection in PEL
The definition of type-1/type-2 EBV infection in PEL was determined in 15 PEL samples by size differences of the PCR amplimers of the viral genes EBNA-2 and EBNA-3C (not Leukemia shown). Eleven PEL were infected by type-1 EBV (11/15; 73%) and four PEL were infected by type-2 EBV (4/15; 27%) ( Table 2) .
Discussion
Although EBV infection occurs in the great majority of PEL, a pathogenetic role of the virus in the development and mainte-nance of these diseases remains to be determined. Similar to Burkitt lymphoma, viral gene expression in EBV-infected PEL is restricted to EBNA-1 and may therefore be classified as latency I. 12, [19] [20] [21] Because PEL fail to express the EBNA-2 and LMP-1 proteins, which play a significant role in EBV mediated transformation, 12, 21 it is conceivable that other viral determinants may contribute to EBV pathogenicity in these lymphomas. Recently, it has been proposed that mutations in EBNA-1 may affect the pathogenicity of EBV in tumors displaying the latency I phenotype. [22] [23] [24] This hypothesis, however, has been recently questioned by other investigators. [25] [26] [27] [28] On this basis, we screened a panel of PEL across several EBV loci. Our results indicate that: (1) individual PEL cases consistently harbor a single EBV strain; (2) EBNA-1 displays a high degree of heterogeneity in different PEL cases; (3) no specific EBV genotype preferentially associates with PEL.
The detection of one single EBV genotype in each individual case of PEL is consistent with monoclonality of infection and, at least in HIV positive individuals, indirectly suggests that viral infection precedes clonal expansion. In this respect, EBV infection in PEL resembles infection of other EBV-positive lymphomas developing both in humans and in animal models. 33, 35, [40] [41] [42] [43] [44] In the case of AIDS-related PEL, it is notable that one single EBV strain infects the lymphoma clone, whereas multiple EBV strains are harbored by peripheral blood mononuclear cells of HIV-infected individuals (this study and Refs 36 and 37).
In contrast to the intratumor homogeneity of EBV strains infecting PEL, analysis of multiple PEL samples indicates that the virus displays a marked degree of intertumor heterogeneity. Such heterogeneity is particularly marked in the case of EBNA-1. The precise biologic relevance of EBNA-1 heterogeneity in PEL deserves further study and is questioned, at least in part, by available epidemiological controls. In fact, comparative analysis of EBV variability in AIDS-related PEL and in PBMNC of HIV-positive individuals without lymphoma suggests that the representation of EBV genotypes in PEL overall reflects the prevalence of EBV variants in the HIV-positive population. Large, multicentric studies comparing EBNA-1 sequences in PEL, as well as in immunodeficient and immunocompetent individuals without lymphoma, are required to conclusively define whether the EBNA-1 heterogeneity of PEL simply reflects geographical variations of EBV strains, as it has been proposed for other EBV positive lymphomas. [25] [26] [27] [28] Independent of these observations, however, the high number of genotypes definable by EBNA-1 sequence variation provides a highly sensitive and specific marker for molecular epidemiology studies of EBV infection in PEL and for investigating intrahost EBV infection in these patients.
The results presented in this study unequivocally indicate that PEL does not preferentially associate with a given EBV genotypic variant. In fact, PEL display both wtLMP-1 and ⌬30LMP-1, which are the most common variants of the gene in humans, and do not show an excess of ⌬69LMP-1, a variant of LMP-1 suggested to harbor high transforming potential. 45 The lack of association between PEL and a given EBNA-1 genotype is at variance with initial observations performed in other lymphomas expressing the latency I phenotype, ie EBNA-1 + EBNA-2 − LMP-1 − . In fact, it has been proposed by some studies that Burkitt lymphoma may cluster with specific EBNA-1 variants, 22, 23 although other investigators have questioned this hypothesis. [25] [26] [27] [28] Because PEL fails to express the EBV transforming antigens LMP-1 and EBNA-2 and also fails to associate with specific EBNA-1 variants, the precise tumorigenic mechanism of EBV in the context of PEL remains to be defined.
Overall, these data question the pathogenetic role of EBV in PEL based on conventional models of EBV pathogenicity that are recognized in EBV-infected lymphomas. Recently, however, it has been hypothesized that cell transformation in tumors expressing the EBV latency I phenotype may be mediated by pathways alternative to EBNA-1. Such alternative transforming pathways may be related, at least in part, to a class of noncoding, though highly expressed small mRNAS termed EBER. 15 Because EBER are expressed in PEL, 12 future studies need to address the pathogenetic contribution of these mRNAs in the development and growth of these lymphomas.
